190 results on '"George, Lindsey A."'
Search Results
2. Coagulation factor VIII: biological basis of emerging hemophilia A therapies
3. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo
4. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells
5. Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis
6. Overcoming Hemophilia A Gene Therapy Limitations with an Enhanced Function Factor VIII Variant
7. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua
8. Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab
9. Coagulation Cascade and Fibrinolysis Pathway: Assessment in the Laboratory
10. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
11. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding
12. Hemophilia A Gene Therapy — Some Answers, More Questions
13. Retraction notice to "Maternal Nutrient Restriction Predisposes Ventricular Remodeling in Adult Sheep Offspring" [The Journal of Nutritional Biochemistry 24 (2013) 1258-1265]
14. Adeno-Associated Virus Gene Therapy for Hemophilia
15. Oyster reef restoration: effect of alternative substrates on oyster recruitment and nekton habitat use
16. Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011
17. Factor VIII Mimetic Rescue of Hemophilia B Causing Factor IX Variants
18. Inhibiting Activated Protein C Cleavage of Factor VIII for Hemophilia a Gene Therapy
19. Antigen Trafficking and Possibly Intrinsic Immunostimulatory Properties Shape High Immunogenicity of Factor VIII
20. Coagulation Factor VIII Enhances the Cleavage of Von Willebrand Factor By ADAMTS13 In Vivo
21. Total Knee Arthroplasty after Gene Therapy for Hemophilia B
22. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
23. Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children
24. Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success
25. Design and Benchmarking of a Network-In-the-Loop Simulation for Use in a Hardware-In-the-Loop System
26. Plain language summary for the manuscript: Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua
27. Hemophilia gene therapy: ushering in a new treatment paradigm?
28. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A
29. Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy
30. Haemophilia care: the only constant is change
31. Health-Related Quality of Life in Adults with Hemophilia B after Receiving Gene Therapy with Fidanacogene Elaparvovec
32. Activated protein C has a regulatory role in factor VIII function
33. No CpGs for AAVs?
34. Current Clinical Applications of In Vivo Gene Therapy with AAVs
35. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
36. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B
37. Combined anti‐CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors
38. Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
39. In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation
40. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity
41. Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis
42. Activity of a FIX-Padua Transgene Product in Commonly Used FIX:C One-Stage and Chromogenic Assay Systems Following PF-06838435 (SPK-9001) Gene Delivery
43. A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
44. Hemophilia gene therapy comes of age
45. A well recognised but forgotten cause of undetectable Magnesium
46. Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression
47. Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
48. The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors.
49. The Effect of Temperature on Solenopsis invitica (Hymenoptera: Formicidae) and their Foraging Habits in Central Texas.
50. FIXing Hemophilia B: Sustained Factor IX Expression of 30 Percent After Gene Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.